Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Saved in:
| Title: | Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. |
|---|---|
| Authors: | Appelmann I; Cancer Biology & Genetics Program, and., Rillahan CD; Cancer Biology & Genetics Program, and., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY; and., Carbonetti G; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY; and., Chen C; Cancer Biology & Genetics Program, and., Lowe SW; Cancer Biology & Genetics Program, and Howard Hughes Medical Institute, and., Sherr CJ; Cancer Biology & Genetics Program, and Howard Hughes Medical Institute, and Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN. |
| Source: | Blood [Blood] 2015 Feb 26; Vol. 125 (9), pp. 1444-51. Date of Electronic Publication: 2014 Dec 12. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1528-0020 |
|---|---|
| DOI: | 10.1182/blood-2014-09-601062 |
